StockData
Cytosorbents Corp logo

Cytosorbents Corp (CTSO) stock

CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 2/30
$4.52−0.33 (-6.80%)

Close on Nov 17, 2026Market cap $284.05MP/E –Yield –

Cytosorbents operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cytosorbents's operating income for the twelve months ending Jun 30, 2026 was -$12.93M. For fiscal 2025 it was -$14.75M. The highest annual figure on record is -$2.82M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$14.75M–
FY2024Dec 31, 2024-$16.45M–
FY2023Dec 31, 2023-$31.95M–
FY2022Dec 31, 2022-$31.52M–
FY2021Dec 31, 2021-$22.74M–
FY2020Dec 31, 2020-$10.37M–
FY2019Dec 31, 2019-$18.97M–
FY2018Dec 31, 2018-$15.58M–
FY2017Dec 31, 2017-$9.84M–
FY2016Dec 31, 2016-$11.49M–
FY2015Dec 31, 2015-$9.30M–
FY2014Dec 31, 2014-$6.89M–
FY2013Dec 31, 2013-$4.71M–
FY2012Dec 31, 2012-$3.49M–
FY2011Dec 31, 2011-$4.44M–
FY2010Dec 31, 2010-$2.82M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.64M–
Q1 FY2026Mar 31, 2026-$3.04M–
Q4 FY2025Dec 31, 2025-$4.39M–
Q3 FY2025Sep 30, 2025-$2.86M–
Q2 FY2025Jun 30, 2025-$3.62M–
Q1 FY2025Mar 31, 2025-$3.89M–
Q4 FY2024Dec 31, 2024-$3.40M–
Q3 FY2024Sep 30, 2024-$4.83M–
Q2 FY2024Jun 30, 2024-$3.57M–
Q1 FY2024Mar 31, 2024-$4.66M–
Q4 FY2023Dec 31, 2023-$9.41M–
Q3 FY2023Sep 30, 2023-$7.35M–
Q2 FY2023Jun 30, 2023-$6.56M–
Q1 FY2023Mar 31, 2023-$7.89M–
Q4 FY2022Dec 31, 2022-$6.36M–
Q3 FY2022Sep 30, 2022-$9.02M–
Q2 FY2022Jun 30, 2022-$8.36M–
Q1 FY2022Mar 31, 2022-$7.79M–
Q4 FY2021Dec 31, 2021-$9.56M–
Q3 FY2021Sep 30, 2021-$5.41M–
Q2 FY2021Jun 30, 2021-$4.92M–
Q1 FY2021Mar 31, 2021-$2.85M–
Q4 FY2020Dec 31, 2020-$2.63M–
Q3 FY2020Sep 30, 2020-$1.96M–
Q2 FY2020Jun 30, 2020-$3.30M–
Q1 FY2020Mar 31, 2020-$2.48M–
Q4 FY2019Dec 31, 2019-$5.43M–
Q3 FY2019Sep 30, 2019-$5.63M–
Q2 FY2019Jun 30, 2019-$3.63M–
Q1 FY2019Mar 31, 2019-$4.29M–
Q4 FY2018Dec 31, 2018-$5.59M–
Q3 FY2018Sep 30, 2018-$2.71M–
Q2 FY2018Jun 30, 2018-$4.19M–
Q1 FY2018Mar 31, 2018-$3.10M–
Q4 FY2017Dec 31, 2017-$3.81M–
Q3 FY2017Sep 30, 2017-$2.15M–
Q2 FY2017Jun 30, 2017-$2.33M–
Q1 FY2017Mar 31, 2017-$1.56M–
Q4 FY2016Dec 31, 2016-$4.57M–
Q3 FY2016Sep 30, 2016-$2.14M–

More Cytosorbents figures

See a number that looks wrong?